Our consortium, made up of 5 partners from 4 countries (France, Canada, Italy and Romania), conducts coordinated translational research studies aiming to provide novel intervention components for at-risk individuals during the critical adolescent period, using a translational and neurodevelopmentally-informed framework. Using exceptional longitudinal cohorts (Bucharest Early Intervention Project (BEIP), IMAGEN European cohort and CoVenture/NeuroVenture Canadian cohort) which have completed long-term follow-up of adolescents at varying risk for depression, we search for neural and cognitive features involved in the transition to early-onset depression. We also re-analyze data from previous randomized trials and recruit new samples to determine the role of these biomarkers in treatment response in adolescents and adults.
Hypotheses on the causal role of neural and environmental markers on cognitive and behavioral phenotypes, and intervention response are tested in preclinical studies, while new neurocognitive targets for intervention are applied in at-risk adolescent samples.
The ADORe Consortium partners have received funding through their respective research organization, as follows
- $National Research Agency (ANR), France;
- $Canadian Institutes of Health Research (CIHR), Canada
- $Ministry of Health (MOH), Italy;
- $Executive Agency for Higher Education, Research Development & Innovation Funding (UEFISCDI), Romania